Optimizing antibiotic dosing regimens for nosocomial pneumonia: a window of opportunity for pharmacokinetic and pharmacodynamic modeling

References

• Eber MR, Laxminarayan R, Perencevich EN, et al. Clinical and economic outcomes attributable to health care-associated sepsis and pneumonia. Arch Intern Med. 2010 Feb 22;170(4):347–353.
   PubMedGoogle Scholar
• Giuliano KK, Baker D, Quinn B. The epidemiology of nonventilator hospital-acquired pneumonia in the United States. Am J Infect Control. 2018 Mar;46(3):322–327.
   PubMed Web of Science ®Google Scholar
• Magill SS, O’Leary E, Ray SM, et al. Antimicrobial use in US hospitals: comparison of results from emerging infections program prevalence surveys, 2015 and 2011. Clin Infect Dis. 2021 May 18;72(10):1784–1792.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society. Clin Infect Dis. 2016 Sep 1;63(5):e61–e111.
   PubMed Web of Science ®Google Scholar
• Ferrer M, Torres A. Epidemiology of ICU-acquired pneumonia. Curr Opin Crit Care. 2018 Oct;24(5):325–331.
   PubMed Web of Science ®Google Scholar
• Corrado RE, Lee D, Lucero DE, et al. Burden of adult community-acquired, health-care-associated, hospital-acquired, and ventilator-associated pneumonia: New York city, 2010 to 2014. Chest. 2017 Nov;152(5):930–942.
   PubMed Web of Science ®Google Scholar
• Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014 Mar 27;370(13):1198–1208.
   PubMed Web of Science ®Google Scholar
• Luyt CE, Hekimian G, Koulenti D, et al. Microbial cause of ICU-acquired pneumonia: hospital-acquired pneumonia versus ventilator-associated pneumonia. Curr Opin Crit Care. 2018 Oct;24(5):332–338.
   PubMed Web of Science ®Google Scholar
• Warren DK, Shukla SJ, Olsen MA, et al. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med. 2003 May;31(5):1312–1317.
   PubMed Web of Science ®Google Scholar
• Weiner LM, Webb AK, Limbago B, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2011-2014. Infect Control Hosp Epidemiol. 2016 Nov;37(11):1288–1301.
   PubMed Web of Science ®Google Scholar
• Weiner-Lastinger LM, Abner S, Edwards JR, et al. Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: summary of data reported to the national healthcare safety network, 2015-2017. Infect Control Hosp Epidemiol. 2020 Jan;41(1):1–18.
   PubMed Web of Science ®Google Scholar
• Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis. 2010 Aug 1;51(Suppl 1):S81–7.
   PubMed Web of Science ®Google Scholar
• Muller AE, Punt N, Mouton JW. Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. J Antimicrob Chemother. 2013 Apr;68(4):900–906.
   PubMed Web of Science ®Google Scholar
• Olofsson SK, Cars O. Optimizing drug exposure to minimize selection of antibiotic resistance. Clin Infect Dis. 2007 Sep 01;45(Suppl 2):S129–36.
   PubMedGoogle Scholar
• Asin-Prieto E, Rodriguez-Gascon A, Isla A. Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents. J Infect Chemother. 2015 May;21(5):319–329.
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American society of health-system pharmacists, the infectious diseases society of America, the pediatric infectious diseases society, and the society of infectious diseases pharmacists. Am J Health Syst Pharm. 2020 May 19;77(11):835–864.
   PubMed Web of Science ®Google Scholar
• Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995 Mar;39(3):650–655.
   PubMed Web of Science ®Google Scholar
• Housman ST, Kuti JL, Nicolau DP. Optimizing antibiotic pharmacodynamics in hospital-acquired and ventilator-acquired bacterial pneumonia. Clin Chest Med. 2011 Sep;32(3):439–450.
   PubMed Web of Science ®Google Scholar
• Abdul-Aziz MH, Sulaiman H, Mat-Nor MB, et al. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive Care Med. 2016 Oct;42(10):1535–1545.
   PubMed Web of Science ®Google Scholar
• Lee YR, Miller PD, Alzghari SK, et al. Continuous infusion versus intermittent bolus of beta-lactams in critically ill patients with respiratory infections: a systematic review and meta-analysis. Eur J Drug Metab Pharmacokinet. 2018 Apr;43(2):155–170.
   PubMed Web of Science ®Google Scholar
• Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia: developing drugs for treatment guidance for industry. Maryland, MD. Food and Drug Administration Center for Drug Evaluation and Research (CDER); 2020.
   Google Scholar
• Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products. United Kingdom. European Medicines Agency; 2016 .
   Google Scholar
• Roberts JA. Using PK/PD to optimize antibiotic dosing for critically ill patients. Curr Pharm Biotechnol. 2011;Dec;12(12):2070–2079.
   PubMed Web of Science ®Google Scholar
• Rodvold KA, George JM, Yoo L. Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents. Clin Pharmacokinet. 2011 Oct;50(10):637–664.
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Hope WW, Boyd SE. Considerations for effect site pharmacokinetics to estimate drug exposure: concentrations of antibiotics in the lung. Curr Opin Pharmacol. 2017 Oct;36:114–123.
   PubMed Web of Science ®Google Scholar
• Kiem S, Schentag JJ. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother. 2008;52(1):24–36.
   PubMed Web of Science ®Google Scholar
• Kuti JL, Nicolau DP. Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients. Int J Antimicrob Agents. 2015 May;45(5):512–518.
   PubMed Web of Science ®Google Scholar
• Crandon JL, Kim A, Nicolau DP. Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs. J Antimicrob Chemother. 2009 Oct;64(4):837–839.
   PubMed Web of Science ®Google Scholar
• Baldwin DR, Honeybourne D, Wise R. Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrob Agents Chemother. 1992 Jun;36(6):1171–1175.
   PubMed Web of Science ®Google Scholar
• Crandon JL, Banevicius MA, Fang AF, et al. Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. Antimicrob Agents Chemother. 2009 Dec;53(12):5102–5107.
   PubMed Web of Science ®Google Scholar
• Gotfried MH, Danziger LH, Rodvold KA. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest. 2001 Apr;119(4):1114–1122.
   PubMed Web of Science ®Google Scholar
• Carcas AJ, Garcia-Satue JL, Zapater P, et al. Tobramycin penetration into epithelial lining fluid of patients with pneumonia. Clin Pharmacol Ther. 1999 Mar;65(3):245–250.
   PubMed Web of Science ®Google Scholar
• Katsube T, Nicolau DP, Rodvold KA, et al. Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia. J Antimicrob Chemother. 2021 Oct 11;76(11):2902–2905.
   PubMed Web of Science ®Google Scholar
• Panidis D, Markantonis SL, Boutzouka E, et al. Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest. 2005 Aug;128(2):545–552.
   PubMed Web of Science ®Google Scholar
• Boselli E, Breilh D, Rimmele T, et al. Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia. Crit Care Med. 2005 Jan;33(1):104–109.
   PubMed Web of Science ®Google Scholar
• Boselli E, Breilh D, Djabarouti S, et al. Reliability of mini-bronchoalveolar lavage for the measurement of epithelial lining fluid concentrations of tobramycin in critically ill patients. Intensive Care Med. 2007 Sep;33(9):1519–1523.
   PubMed Web of Science ®Google Scholar
• Conte JE Jr., Golden JA, Kelly MG, et al. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents. 2005 Jun;25(6):523–529.
   PubMed Web of Science ®Google Scholar
• Freire AT, Melnyk V, Kim MJ, et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis. 2010 Oct;68(2):140–151.
   PubMed Web of Science ®Google Scholar
• Bhavnani SM, Rubino CM, Hammel JP, et al. Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. Antimicrob Agents Chemother. 2012 Feb;56(2):1065–1072.
   PubMed Web of Science ®Google Scholar
• Byl B, Jacobs F, Roucloux I, et al. Penetration of meropenem in lung, bronchial mucosa, and pleural tissues. Antimicrob Agents Chemother. 1999 Mar;43(3):681–682.
   PubMed Web of Science ®Google Scholar
• Motos A, Kuti JL, Li Bassi G, et al. Is one sample enough? β-lactam target attainment and penetration into epithelial lining fluid based on multiple bronchoalveolar lavage sampling time points in a swine pneumonia model. Antimicrob Agents Chemother. 2019 Feb;63:2.
   Web of Science ®Google Scholar
• Dhanani J, Roberts JA, Chew M, et al. Antimicrobial chemotherapy and lung microdialysis: a review. Int J Antimicrob Agents. 2010 Dec;36(6):491–500.
   PubMed Web of Science ®Google Scholar
• Marlin GE, Burgess KR, Burgoyne J, et al. Penetration of piperacillin into bronchial mucosa and sputum. Thorax. 1981 Oct;36(10):774–780.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014 Jun;14(6):498–509.
   PubMed Web of Science ®Google Scholar
• Felton TW, Ogungbenro K, Boselli E, et al. Comparison of piperacillin exposure in the lungs of critically ill patients and healthy volunteers. J Antimicrob Chemother. 2018 May 1;73(5):1340–1347.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Patel YT, Fiedler-Kelly J, et al. Population pharmacokinetic analysis for plasma and epithelial lining fluid ceftolozane/tazobactam concentrations in patients with ventilated nosocomial pneumonia. J Clin Pharmacol. 2021 Feb;61(2):254–268.
   PubMed Web of Science ®Google Scholar
• Mouton JW, Dudley MN, Cars O, et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother. 2005 May;55(5):601–607.
   PubMed Web of Science ®Google Scholar
• Bulitta JB, Hope WW, Eakin AE, et al. Generating robust and informative nonclinical in vitro and in vivo bacterial infection model efficacy data to support translation to humans. Antimicrob Agents Chemother. 2019 May;63(5). 10.1128/AAC.02307-18.
   Web of Science ®Google Scholar
• Drusano GL. Antimicrobial pharmacodynamics: critical interactions of ‘bug and drug.’ Nat Rev Microbiol. 2004 Apr;2(4):289–300.
   PubMed Web of Science ®Google Scholar
• Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. quiz 11-2. Clin Infect Dis. 1998 Jan;26(1):1–10.
   PubMed Web of Science ®Google Scholar
• Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis. 1998 Jul;27(1):10–22.
   PubMed Web of Science ®Google Scholar
• Coleman K, Levasseur P, Girard AM, et al. Activities of ceftazidime and avibactam against beta-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model. Antimicrob Agents Chemother. 2014 Jun;58(6):3366–3372.
   PubMed Web of Science ®Google Scholar
• Bhagunde P, Chang K-T, Hirsch EB, et al. Novel modeling framework to guide design of optimal dosing strategies for β-lactamase inhibitors. Antimicrob Agents Chemother. 2012 May;56(5):3366–3372.
   Web of Science ®Google Scholar
• Ambrose PG, Lomovskaya O, Griffith DC, et al. beta-Lactamase inhibitors: what you really need to know. Curr Opin Pharmacol. 2017 Oct;36:86–93.
   PubMed Web of Science ®Google Scholar
• Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993 May;37(5):1073–1081.
   PubMed Web of Science ®Google Scholar
• Rayner CR, Forrest A, Meagher AK, et al. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet. 2003;42(15):1411–1423.
   PubMed Web of Science ®Google Scholar
• Kashuba AD, Nafziger AN, Drusano GL, et al. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother. 1999 Mar;43(3):623–629.
   PubMed Web of Science ®Google Scholar
• Noel AR, Attwood M, Bowker KE, et al. Pharmacodynamics of plazomicin and a comparator aminoglycoside, amikacin, studied in an in vitro pharmacokinetic model of infection. Int J Antimicrob Agents. 2019 Nov;54(5):626–632.
   PubMed Web of Science ®Google Scholar
• Nielsen EI, Cars O, Friberg LE. Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization. Antimicrob Agents Chemother. 2011 Oct;55(10):4619–4630.
   PubMed Web of Science ®Google Scholar
• Sader HS, Rhomberg PR, Farrell DJ, et al. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob Agents Chemother. 2011 May;55(5):2390–2394.
   PubMed Web of Science ®Google Scholar
• Juan C, Zamorano L, Pérez JL, et al. Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother. 2010 Feb;54(2):846–851.
   PubMed Web of Science ®Google Scholar
• Moya B, Zamorano L, Juan C, et al. Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob Agents Chemother. 2010 Mar;54(3):1213–1217.
   PubMed Web of Science ®Google Scholar
• Giske CG, Ge J, Nordmann P. Activity of cephalosporin CXA-101 (FR264205) and comparators against extended-spectrum-{beta}-lactamase-producing Pseudomonas aeruginosa. J Antimicrob Chemother. 2009 Aug;64(2):430–431.
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Ge Y. Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother. 2010 Sep;65(9):1972–1974.
   PubMed Web of Science ®Google Scholar
• Craig WA, Andes DR. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice. Antimicrob Agents Chemother. 2013 Apr;57(4):1577–1582.
   PubMed Web of Science ®Google Scholar
• VanScoy B, Mendes RE, Nicasio AM, et al. Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model. Antimicrob Agents Chemother. 2013 Jun;57(6):2809–2814.
   PubMed Web of Science ®Google Scholar
• Melchers MJ, Mavridou E, van Mil AC, et al. Pharmacodynamics of ceftolozane combined with tazobactam against Enterobacteriaceae in a neutropenic mouse thigh model. Antimicrob Agents Chemother. 2016 Dec;60(12):7272–7279.
   PubMed Web of Science ®Google Scholar
• Vanscoy B, Mendes RE, McCauley J, et al. Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with ceftolozane. Antimicrob Agents Chemother. 2013 Dec;57(12):5924–5930.
   PubMed Web of Science ®Google Scholar
• Bretonniere C, Boutoille D, Caillon J, et al. In vivo efficacy of ceftolozane against Pseudomonas aeruginosa in a rabbit experimental model of pneumonia: comparison with ceftazidime, piperacillin/tazobactam and imipenem. Int J Antimicrob Agents. 2014 Sep;44(3):218–221.
   PubMed Web of Science ®Google Scholar
• Jacqueline C, Roquilly A, Desessard C, et al. Efficacy of ceftolozane in a murine model of Pseudomonas aeruginosa acute pneumonia: in vivo antimicrobial activity and impact on host inflammatory response. J Antimicrob Chemother. 2013 Jan;68(1):177–183.
   PubMed Web of Science ®Google Scholar
• Motos A, Li Bassi G, Pagliara F, et al. Short-term effects of appropriate empirical antimicrobial treatment with ceftolozane/tazobactam in a swine model of nosocomial pneumonia. Antimicrob Agents Chemother. 2021 Jan 20;65(2). DOI:10.1128/AAC.01899-20.
   PubMed Web of Science ®Google Scholar
• Petraitis V, Petraitiene R, Naing E, et al. Ceftolozane-tazobactam in the treatment of experimental pseudomonas aeruginosa pneumonia in persistently neutropenic rabbits: impact on strains with genetically defined mechanisms of resistance. Antimicrob Agents Chemother. 2019 Sep;63(9). doi:10.1128/AAC.00344-19.
   Web of Science ®Google Scholar
• Melchers MJ, Mavridou E, Seyedmousavi S, et al. Plasma and epithelial lining fluid pharmacokinetics of ceftolozane and tazobactam alone and in combination in mice. Antimicrob Agents Chemother. 2015;59(6):3373–3376.
   PubMed Web of Science ®Google Scholar
• Chandorkar G, Huntington JA, Gotfried MH, et al. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects. J Antimicrob Chemother. 2012 Oct;67(10):2463–2469.
   PubMed Web of Science ®Google Scholar
• Xiao AJ, Miller BW, Huntington JA, et al. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. J Clin Pharmacol. 2016 Jan;56(1):56–66.
   PubMed Web of Science ®Google Scholar
• Caro L, Nicolau DP, De Waele JJ, et al. Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia. J Antimicrob Chemother. 2020 Jun 01;75(6):1546–1553.
   PubMed Web of Science ®Google Scholar
• Kollef MH, Nováček M, Ü K, et al. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2019 Dec;19(12):1299–1311.
   PubMed Web of Science ®Google Scholar
• Timsit JF, Huntington JA, Wunderink RG, et al. Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial. Crit Care. 2021 Sept 11;25(1):290.
   PubMed Web of Science ®Google Scholar
• Lodise t, yang j, puzniak la, et al. healthcare resource utilization of ceftolozane/tazobactam versus meropenem for ventilated nosocomial pneumonia from the randomized, controlled, double-blind ASPECT-NP trial. Infect Dis Ther. 2020 Dec;9(4):953–966.
   PubMed Web of Science ®Google Scholar
• Stachyra T, Péchereau MC, Bruneau JM, et al. Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor. Antimicrob Agents Chemother. 2010 Dec;54(12):5132–5138.
   PubMed Web of Science ®Google Scholar
• Bonnefoy A, Dupuis-Hamelin C, Steier V, et al. In vitro activity of AVE1330A, an innovative broad-spectrum non-beta-lactam beta-lactamase inhibitor. J Antimicrob Chemother. 2004 Aug;54(2):410–417.
   PubMed Web of Science ®Google Scholar
• Aktaş Z, Kayacan C, Oncul O. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents. 2012 Jan;39(1):86–89.
   PubMed Web of Science ®Google Scholar
• de Jonge BL, Karlowsky JA, Kazmierczak KM, et al. In vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible Enterobacteriaceae isolates collected during the INFORM global surveillance study (2012 to 2014). Antimicrob Agents Chemother. 2016 May;60(5):3163–3169.
   PubMed Web of Science ®Google Scholar
• Avycaz (ceftazidime and avibactam) [package insert]. Madison, NJ.Allergan; 2020.
   Google Scholar
• Crandon JL, Schuck VJ, Banevicius MA, et al. Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2012 Dec;56(12):6137–6146.
   PubMed Web of Science ®Google Scholar
• MacVane SH, Kuti JL, Nicolau DP. Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia. Antimicrob Agents Chemother. 2014;58(3):1359–1364.
   PubMed Web of Science ®Google Scholar
• Housman ST, Crandon JL, Nichols WW, et al. Efficacies of ceftazidime-avibactam and ceftazidime against Pseudomonas aeruginosa in a murine lung infection model. Antimicrob Agents Chemother. 2014;58(3):1365–1371.
   PubMed Web of Science ®Google Scholar
• Berkhout J, Melchers MJ, van Mil AC, et al. Pharmacodynamics of ceftazidime and avibactam in neutropenic mice with thigh or lung infection. Antimicrob Agents Chemother. 2016 Jan;60(1):368–375.
   PubMed Web of Science ®Google Scholar
• Nichols WW, Newell P, Critchley IA, et al. Avibactam pharmacokinetic/pharmacodynamic targets. Antimicrob Agents Chemother. 2018 Jun;62(6). doi:10.1128/AAC.02446-17.
   Web of Science ®Google Scholar
• Das S, Li J, Riccobene T, et al. Dose selection and validation for ceftazidime-avibactam in adults with complicated intra-abdominal infections, complicated urinary tract infections, and nosocomial pneumonia. Antimicrob Agents Chemother. 2019 Apr;63:4.
   Web of Science ®Google Scholar
• Nicolau DP, Siew L, Armstrong J, et al. Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens. J Antimicrob Chemother. 2015 Oct;70(10):2862–2869.
   PubMed Web of Science ®Google Scholar
• Berkhout J, Melchers MJ, van Mil AC, et al. Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice. Antimicrob Agents Chemother. 2015 Apr;59(4):2299–2304.
   PubMed Web of Science ®Google Scholar
• Li J, Lovern M, Green ML, et al. Ceftazidime-avibactam population pharmacokinetic modeling and pharmacodynamic target attainment across adult indications and patient subgroups. Clin Transl Sci. 2019 Mar;12(2):151–163.
   PubMed Web of Science ®Google Scholar
• Torres A, Zhong N, Pachl J, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2018 Mar;18(3):285–295.
   PubMed Web of Science ®Google Scholar
• Recarbrio (imipenem, cilastatin, and relebactam) [package insert]. Rahway, NJ. Merck Sharp & Dohme LLC; 2022.
   Google Scholar
• Okamoto K, Gotoh N, Nishino T. Alterations of susceptibility of Pseudomonas aeruginosa by overproduction of multidrug efflux systems, MexAB-OprM, MexCD-OprJ, and MexXY/OprM to carbapenems: substrate specificities of the efflux systems. J Infect Chemother. 2002 Dec;8(4):371–373.
   PubMedGoogle Scholar
• Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis. 2006 Sep 01;43(Suppl 2):S49–56.
   PubMed Web of Science ®Google Scholar
• Horner C, Mushtaq S, Livermore DM, et al. Potentiation of imipenem by relebactam for Pseudomonas aeruginosa from bacteraemia and respiratory infections. J Antimicrob Chemother. 2019 July 01;74(7):1940–1944.
   PubMed Web of Science ®Google Scholar
• Blizzard TA, Chen H, Kim S, et al. Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®. Bioorg Med Chem Lett. 2014 Feb 01;24(3):780–785.
   PubMed Web of Science ®Google Scholar
• Livermore DM, Warner M, Mushtaq S. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother. 2013 Oct;68(10):2286–2290.
   PubMed Web of Science ®Google Scholar
• Bhagunde P, Zhang Z, Racine F, et al. A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam. Int J Infect Dis. 2019 Dec;89:55–61.
   PubMed Web of Science ®Google Scholar
• Daryani N, Patel, M, Flattery A, et al. Imipenem/relebactam pharmacokinetic/ pharmacodynamic analyses from an in vivo neutropenic mouse delayed lung infection model. Thirtieth European Society of Clinical Microbiology and Infectious Diseases Abstract. 2020;Abstract 2086.
   Google Scholar
• Patel M, Daryani, NM, Hwa-Ping F et al, et al. Imipenem/relebactam pharmacokinetic/ pharmacodynamic analyses from an in vivo neutropenic murine thigh infection model. Thirtieth European Society of Clinical Microbiology and Infectious Diseases Abstract. 2020; Abstract 1693 .
   Google Scholar
• Rizk ML, Rhee EG, Jumes PA, et al. Intrapulmonary pharmacokinetics of relebactam, a novel β-lactamase inhibitor, dosed in combination with imipenem-cilastatin in healthy subjects. Antimicrob Agents Chemother. 2018 Mar;62:3.
   Web of Science ®Google Scholar
• Motsch J, Murta de Oliveira C, Stus V, et al. RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections. Clin Infect Dis. 2020 Apr 15;70(9):1799–1808.
   PubMed Web of Science ®Google Scholar
• Titov I, Wunderink RG, Roquilly A, et al. A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem/cilastatin/relebactam versus piperacillin/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 Study). Clin Infect Dis. 2021 Dec 06;73(11):e4539–e4548.
   PubMed Web of Science ®Google Scholar
• Patel M, Bellanti F, Daryani NM, et al. Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital-acquired/ventilator-associated bacterial pneumonia. Clin Transl Sci. 2022 Feb;15(2):396–408.
   PubMed Web of Science ®Google Scholar
• Ito A, Sato T, Ota M, et al. Antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against gram-negative bacteria. Antimicrob Agents Chemother. 2018 Jan;62(1). doi:10.1128/AAC.01454-17.
   Web of Science ®Google Scholar
• Sato T, Yamawaki K. Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin. Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S538–S543.
   PubMedGoogle Scholar
• Aoki T, Yoshizawa H, Yamawaki K, et al. Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: structure activity relationship. Eur J Med Chem. 2018 Jul 15;155:847–868.
   PubMed Web of Science ®Google Scholar
• Fotroja (cefiderocol) [package insert]. Florham Park, NJ. Shionogi & Co. L; 2021.
   Google Scholar
• Nakamura R, Ito-Horiyama T, Takemura M, et al. In vivo pharmacodynamic study of cefiderocol, a novel parenteral siderophore cephalosporin, in murine thigh and lung infection models. Antimicrob Agents Chemother. 2019 Sep;63(9). doi:10.1128/AAC.02031-18.
   Web of Science ®Google Scholar
• Monogue ML, Tsuji M, Yamano Y, et al. Efficacy of humanized exposures of cefiderocol (S-649266) against a diverse population of gram-negative bacteria in a murine thigh infection model. Antimicrob Agents Chemother. 2017 Nov;61(11). doi:10.1128/AAC.01022-17.
   Web of Science ®Google Scholar
• Petraitis V, Petraitiene R, Kavaliauskas P, et al. Efficacy of cefiderocol in experimental stenotrophomonas maltophilia pneumonia in persistently neutropenic rabbits. Antimicrob Agents Chemother. 2022 Oct 18;66(10):e0061822.
   PubMed Web of Science ®Google Scholar
• Tsuji M, Singley C, Horiyama T, et al. 248S-649266, a novel siderophore cephalosporin: efficacy against Klebsiella pneumoniae producing NDM-1 or KPC in rat lung infection model with recreated humanized exposure profile of 2 gram dose with 1 hour and 3 hours infusion. Open Forum Infect Dis. 2014;1(suppl_1):S106–S107.
   Google Scholar
• Katsube T, Saisho Y, Shimada J, et al. Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects. J Antimicrob Chemother. 2019 Jul 1;74(7):1971–1974.
   PubMed Web of Science ®Google Scholar
• Kawaguchi N, Katsube T, Echols R, et al. Intrapulmonary pharmacokinetic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, in patients with pneumonia and healthy subjects. J Clin Pharmacol. 2022 May;62(5):670–680.
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Matsunaga Y, Ariyasu M, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2021 Feb;21(2):213–225.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021 Feb;21(2):226–240.
   PubMed Web of Science ®Google Scholar
• Zerbaxa (ceftolozane and tazobactam) [package insert]. Rahway, NJ. Merck Sharp & Dohme Corp; 2022.
   Google Scholar
• Lucasti C, Vasile L, Sandesc D, et al. Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection. Antimicrob Agents Chemother. 2016 Oct;60(10):6234–6243.
   PubMed Web of Science ®Google Scholar
• Lodise TP, Patel N, Renaud-Mutart A, et al. Pharmacokinetic and pharmacodynamic profile of ceftobiprole. Diagn Microbiol Infect Dis. 2008 May;61(1):96–102.
   PubMed Web of Science ®Google Scholar
• Awad SS, Rodriguez AH, Chuang YC, et al. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis. 2014 Jul 01;59(1):51–61.
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Nicolau DP, Lodise TP, et al. Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole. Antimicrob Agents Chemother. 2009 Aug;53(8):3294–3301.
   PubMed Web of Science ®Google Scholar